Discontinued — last reported Q1 '24

Business Segments · Restructuring expenses

Healthcare and Life Sciences — Restructuring expenses

STERIS Healthcare and Life Sciences — Restructuring expenses remained flat by 0.0% to $4.75M in Q1 2024 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ2 2023
Last reportedQ1 2024
Rolls up toRestructuring Charges

How to read this metric

An increase suggests active operational transformation or cost-cutting initiatives, while a decrease indicates a more stable organizational structure.

Detailed definition

This metric represents the costs incurred by the Healthcare and Life Sciences segment to reorganize operations, consolid...

Peer comparison

Peers in the medical technology sector frequently report similar charges during periods of post-acquisition integration or strategic pivots toward higher-margin product lines.

Metric ID: ste_segment_healthcare_and_life_sciences_restructuring_expenses

Historical Data

1 years
 FY'24
Value$19.00M

Similar Metrics at Other Companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMOView metric
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMOView metric
General Electric logo
General ElectricGEView metric
Pfizer logo
PfizerPFEView metric
IR
Ingersoll RandIRView metric
IR
Ingersoll RandIRView metric

Frequently Asked Questions

What is STERIS's healthcare and life sciences — restructuring expenses?
STERIS (STE) reported healthcare and life sciences — restructuring expenses of $4.75M in Q1 2024.
What does healthcare and life sciences — restructuring expenses mean?
Costs associated with reorganizing or downsizing operations within the Healthcare and Life Sciences business unit.